Market Context — 2026-08-25 Update (v37)
Iran sanctions escalation now the dominant near-term catalyst, oil two-sided. Bessent unveiled "Economic Outcast"/D-Day sanctions campaign (~60 entities, extending to digital assets, gold, aviation, shipping) with explicit warning China isn't exempt — a real friction point given the fragile US-China trade truce ahead of a Trump-Xi September meeting. Brent broke $93-94, WTI high-$80s, diesel cracks still record (~$100/bbl, $5.47/gal retail, $7 in parts of CA). But diplomatic threads are thickening in parallel: Oman-Iran FM talks on reopening Hormuz, Qatar demanding pre-war norms, Pezeshkian wanting an exit — Hormuz breakthrough remains a live bearish-oil/bullish-equity tail risk even as headline rhetoric stays hostile. Somali piracy resurgence and China-Iran oil squeeze add friction. Canada trade war now hard-edged: Trump doubling auto tariffs (25%→50%, effective Jan 2027), Carney defiant, retaliation deadline Sept 8 confirmed.
Bond market remains the key transmission channel, unresolved. 30Y still 5.19-5.35% range despite Bessent doubling buybacks to $4B/op — Schiff/Guha/Brusuelas skepticism intact, seen as undermining Warsh's credibility rather than fixing fundamentals. Fed minutes confirmed hawkish 9-3 hold with December hike risk if inflation doesn't cool. Japan JGB/yen "canary" thesis persists as the top macro tripwire.
Chip bifurcation sharpening into NVDA earnings (this week) and Marvell/IREN (8/27), Broadcom (9/2). Custom-silicon diversification accelerating hard: Nvidia-Rebellions talks, Waymo ASIC, Xiaomi Xring D100, SpaceX/Nvidia space Vera Rubin deal — structural bear case for pure-GPU moat, but bullish analyst calls stacking up too (BMO $340 NVDA PT, JPMorgan top-pick Marvell, Truist CRWV $165 PT, Applied Materials AI capex durability). Intel fell on $20B secondary dilution. Goldman data shows mutual funds still "off the charts" underweight NVDA — positioning not yet crowded despite the rally narrative. SMH $129M synthetic short still unresolved/unexpired.
Healthcare/biotech breakout now the cleanest confirmed rotation — Merck ATH, Moderna mRNA-cancer win, XBI +34% YTD, breadth broadening (Amgen, IQVIA, Danaher), fund flows still light (~$4.5B in) relative to prior outflows — room to extend. Retail earnings mixed: Walmart missed comps and fell 10%, Home Depot's beat was tariff-refund-driven, masking underlying softness.
Watch: NVDA earnings this week (historical ~6% post-earnings drawdown), Marvell/IREN 8/27, Broadcom 9/2, Iran secondary-sanctions/China friction, Hormuz diplomacy, Canada Sept 8 retaliation, Japan JGB stress, 30Y yield direction.